China Myasthenia Gravis Therapeutics Market


  • Type: Rare Disease Area
  • Published : April 2021
  • Region: Asia
  • Country: China
  • Report ID : 1570

  • Format: PPT, PDF

China Myasthenia Gravis Therapeutics Market: Segmented by Drug Type (Cholinesterase Inhibitors, Immunosuppressive Drugs), Surgery (Thymectomy), Region (Coastal, Inland)- Size, Growth, Trends, and Forecasts (2019 – 2028)

SKU: 1570 Categories: ,

Report Overview

The China Myasthenia Gravis Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 8.2% during the forecast period.

Myasthenia gravis (MG) is an organ-specific autoimmune disorder of the neuromuscular junction, characterized by specific autoantibodies against skeletal muscular antigens in the postsynaptic membrane. And 85% of all patients experience generalized myasthenia gravis affecting proximal muscles of the extremities and the trunk. The annual incidence of myasthenia gravis in China is 29400 and the prevalence is 165600 in 2019. China has a large number of patients (650,000) who are suffering from MG disease. The admission mortality rate was 14.69%. Most cases of new onset MG occurred in the seventh decade of life. In China, the incidence rate of myasthenic crisis (4.81%) and mortality rate (6.4%) are less as compared to the USA.

Market Drivers

The market is majorly driven by the rising geriatric population (12.57% by end of 2019). The mean age of disease diagnosis was 52.2 years, with adults 55.9 years and children 8.9 years. Key factors that are driving the market growth include rising adoption of immunotherapies, approval of promising drugs, emergence of biologics, increase in incidence (annually in China 29400) and increasing awareness of rare diseases.

However, the side effects caused by several therapeutics are restraining market growth. Some of the products are withdrawn from the market due to serious side effects. In April 2019, high dose combination of Cholinesterase Inhibitors (ChEIs) and Calcineurine Inhibitors (CNIs) such as Mestinon and Prograf are responsible for severe muscle cramps in myasthenia gravis patients. High cost of treatment also impacts the growth of the market.

1. China Myasthenia Gravis Therapeutics Market Overview…………………………….
A. Market Size
2. Market Growth Drivers………………………………………………………………………
A. Increase in Research and Development Activities
B. Increase in Geriatric Population
C. Adaptation of Immunotherapies
D. Approval of Drugs, Emergence of Biologics
E. Increase in Awareness
3. Major Types of Myasthenia Gravis………………………………………………………..
A. Congenital Myasthenia Gravis
B. Transient neonatal Myasthenia Gravis
C. Juvenile Myasthenia Gravis
D. Generalized Myasthenia Gravis
E. Ocular Myasthenia Gravis
4. Myasthenia Gravis Therapeutics Market Segmentation………………………………..
A. By Drug Type
I. Cholinesterase Inhibitors
II. Immunosuppressive Drugs
B. By Surgery
I. Thymectomy
C. By Region
I. Coastal
II. Inland
5. Myasthenia Gravis Major Products Market Share……………………………………..
A. Market Analysis, Insights and Forecast – By Revenue Type
6. Competitive Landscape…………………………………………………………………….
A. Major Players
B. Products in Pipeline
7. Key Company Profiles………………………………………………………………………
A. Alexion Company Overview, Product & Services, Strategies & Financials
B. Harbour Biomed Company Overview, Product & Services, Strategies & Financials
C. RemeGen Company Overview, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape……………………………………….
A. Policy Changes and Reimbursement Scenario
9. Factors Driving Future Growth……………………………………………………………
A. New Trends and Development of Myasthenia Gravis Therapeutics Market
B. Future Opportunities
10. Conclusion

Market Segmentation

By Drug Type:

On the basis of drug type, the China Myasthenia Gravis therapeutics market can be segmented into cholinesterase inhibitors and immunosuppressive drugs.

Cholinesterase inhibitors include Pyridostigmine bromide and in China maximum oral dose per day is 480 mg 3 to 4 times. Immunosuppressive drugs consist of such as Glucocorticoids (Prednisone, Methylprednisolone and Dexamethasone), Azathioprine, Cyclosporin A, Tacrolimus (FK-506), Cyclophosphamide, Mycophenolate Mofetil (MMF), Rituximab.

By Surgery:

On the basis of surgery, the China Myasthenia Gravis therapeutics market can be segmented into Thymectomy. Thymectomy is one of the main treatment methods for myasthenia gravis. It is a surgical procedure where the thymus gland is removed to stop the production of autoantibodies that mistakenly attack the muscle-nerve connections in myasthenia gravis patients.

By Region:

On the basis of region, the China Myasthenia Gravis therapeutics market is segmented into coastal and inland regions. The estimated incidence of myasthenia gravis per 100,000 persons-years varied from 0.10 Tibet to 1.17 in Beijing.  The incidence of myasthenia gravis was higher in Coastal areas than that in the Inland areas, especially in circum-Bohai sea zone including Liaoning, Beijing, Hebei, and Shandong provinces. The estimated prevalence of myasthenia gravis is 5.09 in Henan province, 6.47 in Hubei province, and 2.19–11.07 per 100,000 in Guangzhou city.

Fig- Incidence rates of Myasthenia Gravis for 31 provinces and administrative division in mainland China. (According to THE LANCET regional health report published in 2020).

Major Players

Some of key players in the myasthenia gravis therapeutics market are Alexion Pharmaceuticals, Inc.; Harbour BioMed; HanAll Biopharma; Shanghai Zhongxi Sanwei Pharmaceutical Co., Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; argenx SE; Zai Lab Limited; RemeGen Co., Ltd; Novartis AG; UCB Pharma;

Many new players are emerging in the myasthenia gravis therapeutics market, as a result of a number of growth opportunities. Key players adopting various strategies such as partnership, licensing agreement. For instance, licensing agreement between HanAll Biopharma-Harbour BioMed’s Batoclimab (HBM9161) receives China CDE breakthrough therapy designation for treatment of adult patients with Myasthenia Gravis. And some universities in China are also developing drugs for MG disease (Sun Yat-Sen University in China is conducting phase III clinical trial of Azathioprine and Leflunomide for treatment of myasthenia gravis).

argenx and Zai Lab announce Strategic Collaboration for Efgartigimod in Greater China. Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China, Efgartigimod is an investigational antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and block the IgG recycling process.

Research Methodology

Insights10 will provide you reports within 10 key parameters which are:

  1. Market overview
  2. Market growth drivers & restraints
  3. Epidemiology or disease type
  4. Market segmentation
  5. Market share
  6. Competitive landscape
  7. Key company profiles
  8. Healthcare policies & regulatory framework
  9. Reimbursement scenario
  10. Factors driving future growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision making for business stakeholders. Our focused approach to develop reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Our analysis methodology involves three critical stages:

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers and researchers across countries through which we engage with local experts to gather key data points and assumptions around each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain the high level of accuracy and consistency. The market data is analysed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, market share as well as segment-level analysis of the specific market. Our report includes precise, to the point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

  • Statistical Databases
  • Company Websites/Annual Reports
  • Trade Publications
  • Online Databases
  • Published Research Reports
  • Whitepapers
  • Press Releases of Key Market Players

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameter and micro indicators. The macro parameters includes changes in government policies, demand and supply of the market, government intervention programs and major market share. The micro indicators GDP growth, market size, market volume etc. We also understand nuances specific to each country like US, Canada, India, Germany, etc. and have worked across 60+ countries and hence no only understand global trends, but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. start with large overall market and segment different areas and bottom-up approach i.e. start with population and epidemiology and roll up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach mainly used for new product forecasting and bottom-up approach is used for demand estimation of any product for different countries summed up to form total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and Africa for the period of 2020 to 2028. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape and policy and regulatory scenario and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases and the company level averages etc.

We make sure to finalize the numbers in alignment to the market research. Firstly, our internal experts ensure thorough validation and checking to ensure the accurate and precise analysis and then validation is also done using multiple data analysis model.  Two level validation is done and entails finalization of report scope and to way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analysed and synthesized. A second series of interviews are done if necessary to check and validate. The future opportunities are analysed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results are then, interpreted by considering following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue / volume
  • Analyzing current needs and determining penetration to estimate market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and its impact to the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumptions.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.

    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements